Keppra® (Epilepsy)

Keppra® is indicated in Europe as:

• monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy
• adjunctive therapy for partial onset seizures with or without secondary generalisation in adults, children and infants from 1 month of age with epilepsy
• adjunctive therapy for myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy (JME)
• adjunctive therapy for the treatment of Primary Generalised Tonic-Clonic (PGTC) seizures in adults and adolescents from 12 years of age with Idiopathic Generalised Epilepsy (IGE).

In Europe, Keppra® is also indicated for intravenous administration and is available as 100 mg/mL concentrate for solution for infusion.

Keppra® is indicated in the US as:

• adjunctive therapy in the treatment of partial onset seizures in patients one month of age and older with epilepsy
• adjunctive therapy in the treatment of myoclonic seizures in patients 12 years of age and older with Juvenile Myoclonic Epilepsy (JME)
• adjunctive therapy in the treatment of Primary Generalised Tonic-Clonic (PGTC) seizures in patients 6 years of age and older with Idiopathic Generalised Epilepsy (IGE).

Keppra® is also available in the US as an intravenous formulation for the adjunctive treatment in adults (≥ 16 years of age) with the following seizure types when oral administration of Keppra® is temporarily not feasible:

• partial onset seizures
• myoclonic seizures in patients with juvenile myoclonic epilepsy
• primary generalised tonic-clonic seizures.

SmPC Keppra® (EU). Sourced from www.ema.europa.eu

Keppra XR™

is an antiepileptic drug indicated for adjunctive therapy in the treatment of partial onset seizures in patients ≥ 16 years of age with epilepsy.